Zobrazeno 1 - 10
of 44
pro vyhledávání: '"David H. Law"'
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 1232-1236 (2023)
Programmed death protein-1 (PD-1) checkpoint inhibitors such as pembrolizumab and nivolumab are cornerstones to metastatic melanoma treatment, and they are often considered to be pharmacologically similar and interchangeable when it comes to designin
Externí odkaz:
https://doaj.org/article/81a7ee773b724b4abc580d0c83eb3c38
Autor:
Howa Yeung, Krittin J. Supapannachart, Sandy Francois, Colin H. Adler, Ragini R. Kudchadkar, David H. Lawson, Melinda L. Yushak, Afreen I. Shariff, Suephy C. Chen
Publikováno v:
JID Innovations, Vol 3, Iss 6, Pp 100232- (2023)
Relationships between cutaneous adverse effects (CAEs) and noncutaneous adverse effects (NCAEs) of melanoma immunotherapy may help identify patterns tied to distinct immunologic pathways. The objective of this study was to determine the associations
Externí odkaz:
https://doaj.org/article/23dfe9d3445c4e7cab094e4d698b1611
Autor:
David H. Law
Publikováno v:
HEC Forum. 9:112-119
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ccdafe31498e6c5e4872fdcc9fe95af
https://doi.org/10.1023/a:1008866803818
https://doi.org/10.1023/a:1008866803818
Autor:
William A. Nelson, David H. Law
Publikováno v:
Cambridge Quarterly of Healthcare Ethics. 3:143-148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d8feb6900a8901f2cf4429412003d5e
https://doi.org/10.1017/s0963180100004825
https://doi.org/10.1017/s0963180100004825
Publikováno v:
The New England journal of medicine. 273(6)
ALTHOUGH functioning tumors of endocrine glands have been recognized for many years it is only recently that attention has been paid to the so-called "ectopic" production of hormones by tumors of tissues that are not the natural sites of hormone prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6dd0484fae3482d90b739c24b98c880
https://pubmed.ncbi.nlm.nih.gov/21417063
https://pubmed.ncbi.nlm.nih.gov/21417063
Autor:
Hannah M. Knochelmann, Michael Brandon Ware, Aditya Rali, Susanne Linderman, Jessica G. Shantha, David H. Lawson, Melinda Yushak, Robert Swerlick, Chrystal M. Paulos, Steven Yeh, Ragini Kudchadkar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both
Externí odkaz:
https://doaj.org/article/5682dd66a7c94c14983544e2aef025d4
Autor:
Mehmet Asim Bilen, Julie M. Shabto, Dylan J. Martini, Yuan Liu, Colleen Lewis, Hannah Collins, Mehmet Akce, Haydn Kissick, Bradley C. Carthon, Walid L. Shaib, Olatunji B. Alese, Conor E. Steuer, Christina Wu, David H. Lawson, Ragini Kudchadkar, Viraj A. Master, Bassel El-Rayes, Suresh S. Ramalingam, Taofeek K. Owonikoko, R. Donald Harvey
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due to the lack of optimal biomarkers. The presence of liver metastases has been implicated as a poor prognostic factor in patients with metastat
Externí odkaz:
https://doaj.org/article/3a89538b1b6f4594bd638b17c5ad5f05
Autor:
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in p
Externí odkaz:
https://doaj.org/article/5cdc7070ed8046e696ecf169baa8612b
Autor:
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-23 (2018)
Abstract Background Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination re
Externí odkaz:
https://doaj.org/article/4608673a241f46ca9625955f197bdebe
Autor:
Jonathan S. Zager, Brian R. Gastman, Sancy Leachman, Rene C. Gonzalez, Martin D. Fleming, Laura K. Ferris, Jonhan Ho, Alexander R. Miller, Robert W. Cook, Kyle R. Covington, Kristen Meldi-Plasseraud, Brooke Middlebrook, Lewis H. Kaminester, Anthony Greisinger, Sarah I. Estrada, David M. Pariser, Lee D. Cranmer, Jane L. Messina, John T. Vetto, Jeffrey D. Wayne, Keith A. Delman, David H. Lawson, Pedram Gerami
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP’s pr
Externí odkaz:
https://doaj.org/article/51ad8d737b2d423ab145b5125b6bb24a